ERAS vs. CRVS

Last updated Jun 9, 2026

ERAS (Erasca, Inc.) and CRVS (Corvus Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, ERAS returned 63.40%/yr vs 46.04%/yr for CRVS. At a 0.32 correlation, their price movements are largely independent.

Performance

ERAS vs. CRVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Erasca, Inc. (ERAS) and Corvus Pharmaceuticals, Inc. (CRVS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ERAS achieves a 245.97% return, which is significantly higher than CRVS's 44.81% return.

ERAS

• 1D: 7.52%
• 1M: 27.17%
• YTD: 245.97%
• 6M: 285.33%
• 1Y: 704.37%
• 3Y*: 63.40%
• 5Y*: —
• 10Y*: —

CRVS

• 1D: 0.27%
• 1M: -28.30%
• YTD: 44.81%
• 6M: 30.26%
• 1Y: 185.17%
• 3Y*: 46.04%
• 5Y*: 31.93%
• 10Y*: -1.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ERAS vs. CRVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ERAS Erasca, Inc.	245.97%	48.21%	17.84%	-50.58%	-72.34%	-10.61%
CRVS Corvus Pharmaceuticals, Inc.	44.81%	43.93%	203.98%	107.06%	-64.73%	4.33%

Correlation

The correlation between ERAS and CRVS is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.34
Correlation (3Y) Calculated over the trailing 3-year period	0.32
Correlation (All Time) Calculated using the full available price history since Jul 19, 2021	0.32

Fundamentals

Market Cap ERAS : $3.92B CRVS : $1.00B
EPS ERAS : -$0.96 CRVS : -$0.53
PB Ratio ERAS : 9.95 CRVS : 4.17
Total Revenue (TTM) ERAS : $0.00 CRVS : $0.00
Gross Profit (TTM) ERAS : -$743.00K CRVS : -$26.00K
EBITDA (TTM) ERAS : -$279.47M CRVS : -$47.43M

Return for Risk

ERAS vs. CRVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ERAS

ERAS Risk / Return Rank: 98
ERAS Sharpe Ratio Rank: 100
ERAS Sortino Ratio Rank: 96
ERAS Omega Ratio Rank: 97
ERAS Calmar Ratio Rank: 98
ERAS Martin Ratio Rank: 99

CRVS

CRVS Risk / Return Rank: 86
CRVS Sharpe Ratio Rank: 74
CRVS Sortino Ratio Rank: 96
CRVS Omega Ratio Rank: 93
CRVS Calmar Ratio Rank: 85
CRVS Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ERAS vs. CRVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Erasca, Inc. (ERAS) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ERAS	CRVS	Difference
Sharpe ratio: Return per unit of total volatility	6.83	1.03	+5.80
Sortino ratio: Return per unit of downside risk	4.19	4.25	-0.06
Omega ratio: Gain probability vs. loss probability	1.66	1.48	+0.18
Calmar ratio: Return relative to maximum drawdown	11.96	3.30	+8.66
Martin ratio: Return relative to average drawdown	38.13	7.42	+30.71
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ERAS vs. CRVS - Sharpe Ratio Comparison

The current ERAS Sharpe Ratio is 6.83, which is higher than the CRVS Sharpe Ratio of 1.03. The chart below compares the historical Sharpe Ratios of ERAS and CRVS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ERAS	CRVS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	6.83	1.03	+5.80
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.24	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.01	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	-0.02	-0.05

Drawdowns

ERAS vs. CRVS - Drawdown Comparison

The maximum ERAS drawdown since its inception was -95.65%, roughly equal to the maximum CRVS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for ERAS and CRVS.

Drawdown Indicators

	ERAS	CRVS	Difference
Max Drawdown Largest peak-to-trough decline	-95.65%	-96.97%	+1.32%
Max Drawdown (1Y) Largest decline over 1 year	-59.46%	-56.43%	-3.03%
Max Drawdown (3Y) Largest decline over 3 years	-67.68%	-70.50%	+2.82%
Max Drawdown (5Y) Largest decline over 5 years	—	-92.40%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-96.97%	—
Current Drawdown Current decline from peak	-47.12%	-56.31%	+9.19%
Average Drawdown Average peak-to-trough decline	-74.82%	-69.32%	-5.50%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.61%	25.07%	-6.46%

Volatility

ERAS vs. CRVS - Volatility Comparison

The current volatility for Erasca, Inc. (ERAS) is 20.75%, while Corvus Pharmaceuticals, Inc. (CRVS) has a volatility of 23.70%. This indicates that ERAS experiences smaller price fluctuations and is considered to be less risky than CRVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ERAS	CRVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.75%	23.70%	-2.95%
Volatility (6M) Calculated over the trailing 6-month period	96.00%	111.87%	-15.87%
Volatility (1Y) Calculated over the trailing 1-year period	104.32%	181.10%	-76.78%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	83.42%	131.06%	-47.64%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.42%	111.16%	-27.74%

Dividends

ERAS vs. CRVS - Dividend Comparison

Neither ERAS nor CRVS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ERAS and CRVS in my portfolio?

ERAS and CRVS have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ERAS or CRVS?

CRVS has higher volatility (23.70%) compared to ERAS (20.75%). In terms of maximum drawdown, ERAS dropped -95.65% vs CRVS's -96.97%.

Which has better risk-adjusted returns?

ERAS currently has the higher Sharpe Ratio (6.83 vs 1.03), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.